Small molecule · Inhibitor of cyclin-dependent kinase 4 (CDK4) · developed by BeOne Medicines
BGB-43395 is an orally bioavailable, selective inhibitor of cyclin-dependent kinase 4 (CDK4). By blocking CDK4-mediated phosphorylation of retinoblastoma protein early in G1, it prevents the G1-S transition, arrests the cell cycle and suppresses tumor cell proliferation. It is studied in HR-positive, HER2-negative breast cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07492641 | Phase 3 | HR+/HER2- Breast Cancer | Recruiting | ONC |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
HR+/HER2- Breast Cancer
See ONC's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ONC catalysts and pipeline →